Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium bromide; Drug: Other COPD medication Sponsors: AstraZeneca; RTI Health Solutions Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials